Imugene reports first complete response in azer-cel BTKi cohort

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort of its ongoing Phase 1b azer-cel trial, marking an ...
Yahoo Finance

Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)

10 patients have been treated to date with azer-cel in the Phase 1b diffuse large B-cell lymphoma (DLBCL) trial Cohort A: 6 patients were treated with azer-cel and lymphodepletion (chemotherapy) 1 ...
Benzinga.com

What To Watch Out For In Cannabis Industry: Cowen's Vivien Azer Shares Insights At Benzinga Cannabis Capital Conference

With support for legal marijuana at an all-time high, legal cannabis states will generate $25 billion in sales in 2021, according to Vivien Azer, managing director and senior research analyst at Cowen ...
Business Insider

Here are the 3 top pot stocks to bet on in the US and one to avoid, according to Wall Street's leading cannabis analyst

Wall Street's leading cannabis-industry analyst just started covering five US pot companies. Cowen's Vivien Azer, one of the premier cannabis analysts in the US, released a series of notes on Friday ...